PAMICOGREL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H24N2O4S
Molecular Weight	448.534
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)CN1C=CC=C1C2=NC(=C(S2)C3=CC=C(OC)C=C3)C4=CC=C(OC)C=C4

InChI

InChIKey=ISCHOARKJADAKJ-UHFFFAOYSA-N

InChI=1S/C25H24N2O4S/c1-4-31-22(28)16-27-15-5-6-21(27)25-26-23(17-7-11-19(29-2)12-8-17)24(32-25)18-9-13-20(30-3)14-10-18/h5-15H,4,16H2,1-3H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16121308
Curator's Comment: Description was created based on several sources, including http://link.springer.com/article/10.2165%2F00128413-200112720-00021 and http://www.ncbi.nlm.nih.gov/pubmed/9013200

Pamicogrel is a cyclooxygenase inhibitor with platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion. It also has potential in both prophylaxis and treatment of ischemic brain injury. An NDA was submitted in Japan in April 1997. The effects of the drug on platelet aggregation were originally disclosed in EP-00159677, while the later European patent, EP-00560136, claims its use in brain dysfunction induced by hypoxia arising from disturbance of cerebral circulation, such as cerebral hemorrhage or cerebral infarction.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Prostaglandin G/H synthase (cyclooxygenase) 4 Target ID: CHEMBL2111358 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9013200	Inhibitor 8297	0.69 µM [IC50]
Thromboxane B2 formation 1 Target ID: Thromboxane B2 formation Sources: http://www.ncbi.nlm.nih.gov/pubmed/9013200	Inhibitor 8297
platelet aggregation 76 Target ID: GO:0070527 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8583391	Inhibitor 8297
Cyclooxygenase-1 127 Target ID: CHEMBL221 Sources: http://www.genome.jp/dbget-bin/www_bget?D01090	Inhibitor 8297
Cyclooxygenase-2 196 Target ID: CHEMBL230 Sources: http://www.genome.jp/dbget-bin/www_bget?D01090	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic arterial occlusion 5 Sources: http://www.currenttherapeuticres.com/article/S0011-393X(00)90016-X/fulltext?mobileUi=0	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Determination of the antiplatelet agent. KB-3022, and its metabolite by high-performance liquid chromatography.	1990 Apr	2379283
[Determination of the main metabolite (desethyl KBT-3022) of a new antiplatelet agent, KBT-3022 in plasma by gas chromatography].	1992 Jun	1432594
Photo-stability of the new antiplatelet agent, KBT-3022 (ethyl 2-[4,5-bis(4-methoxyphenyl)thiazole-2-yl]pyrrol-1-ylacetate) in aqueous solutions containing acetonitrile.	1992 Nov	1477921
The effects of KBT-3022, a new anti-platelet agent, on hemorheological properties in guinea pigs.	1995 Jan	7740482
Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis.	1995 Jun	7563977

Patents

Sample Use Guides

In Vivo Use Guide

5 mg once daily was administered orally for 6 weeks.

Route of Administration: Oral

In Vitro Use Guide

Pamicogrel (1 uM) significantly inhibited both neutrophil migration and the increase in [Ca2+] induced by leukotriene B4 (LTB4) in Japanese albino rabbits.

Name

Type

Language

PAMICOGREL

Official Name

English

PAMICOGREL [JAN]

Common Name

English

pamicogrel [INN]

Common Name

English

KBT3022

Code

English

KB3022

Code

English

PAMICOGREL [MI]

Common Name

English

KBT-3022

Code

English

KB-3022

Code

English

ETHYL 2-(4,5-BIS(P-METHOXYPHENYL)-2-THIAZOLYL)PYRROLE-1-ACETATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1323